SARS-CoV-2 antibody profile of naturally infected and vaccinated individuals detected using qualitative, semi-quantitative and multiplex immunoassaysArticle Published on 2022-12-012022-11-15 Journal: Diagnostic microbiology and infectious disease [Category] COVID19(2023년), SARS, 진단, 치료기술, 치료제, [키워드] anti-N antibody anti-RBD anti-S2 Anti-spike antibodies antibody Antibody profile Antigen average Cohort demonstrated exhibited HCW healthcare worker IgG immune immunoassay individual Infection infection cohort mRNA vaccines multiplex natural infection Patient positive produced reactivity SARS-CoV-2 SARS-CoV-2 antibody semi-quantitative Support target vaccinated individual vaccination vaccination. [DOI] 10.1016/j.diagmicrobio.2022.115803 PMC 바로가기
Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylationArticle Published on 2022-11-082022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] 293 cells 293F cell acute respiratory syndrome addition binding caused Cell changed characterization convalescent sera coronavirus Coronavirus disease-19 COVID-19 Critical discrepancy effective Efficacy elicited exhibited expression globe glycosylated glycosylation glycosylation pattern homogeneity host cells IgG immunization immunogenicity insect cell mammalian cells mice Neutralizing antibody response neutralizing antibody titre pandemic Protein Proteins provide reactivity Receptor binding regimen robust S protein S-2P SARS-CoV-2 SARS-CoV-2 spike protein spike Spike. the S protein thermal stability Vaccine Vaccine design Variation virus virus entry while [DOI] 10.1016/j.vaccine.2022.09.057 PMC 바로가기
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19Article Published on 2022-11-022022-11-15 Journal: PLoS ONE [Category] SARS, 진단, 치료기술, [키워드] anti-Nucleocapsid IgG anti-SARS-CoV-2 anti-SARS-CoV-2 IgG antibody Antigen booster vaccination cellular cellular immunity Cohort Concentration convalescent COVID-19 detectable domain Endemic humoral IFN-γ IgG immune response Immunity Immunoglobulin Immunosuppressed Immunosuppression immunosuppressive individual liver Liver transplantation membrane nucleocapsid Prevalence protective immunity reactivity Receptor binding domain recipient remained retrieved robust SARS-CoV-2 significantly increased Spike protein stimulated T cell T cell response therapy vaccination [DOI] 10.1371/journal.pone.0276929 PMC 바로가기
A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patientsArticle Published on 2022-10-132022-11-15 Journal: Upsala Journal of Medical Sciences [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Abbott anti-S Antigen antivirals BNT162b2 mRNA vaccine Cellular immune response cellular response Chronic kidney disease coronavirus 2 coronavirus disease COVID-19 COVID-19 infection develop dose enrolled evaluated Hemodialysis humoral humoral and cellular immune response. IgG antibody immune response Immunological response ImmunoSpot Infection interquartile range IQR kidney Level median MONITOR monoclonal antibody mRNA pandemic Patient patients positive Protein reactivity respiratory respond robust SARS-CoV-2 SARS-CoV-2 BNT162b2 SARS-CoV-2 bnt162b2 mRNA vaccine T-cell T-cell Response the median the Spike the vaccine uremia vaccine dose Vaccines weaker immune response [DOI] 10.48101/ujms.v127.8959 PMC 바로가기
Central and effector memory T cells in peripheral blood of patients with interstitial pneumonia: preliminary clues from a COVID-19 studyArticle Published on 2022-10-102022-11-15 Journal: Respiratory Research [Category] COVID19(2023년), SARS, 바이오마커, [키워드] acute phase addition affected Analysis biological marker CD3+ cells CD4 CD8 Cell cell population central memory Central memory T cells control group control patient controls COVID-19 COVID-19 diagnosis cross-sectional decrease described differential expression disease early phase effector effector memory Effector memory T cells flow cytometry group homeostasis hospital Hospital admission immune increase interstitial interstitial lung involvement interstitial pneumonia lymphocyte subpopulation Lymphocyte subpopulations memory memory T memory T cells Patient patients with pneumonia performed Peripheral blood peripheral lymphocyte Pneumonia positive pre-existing T-cell protocol reactivity recruited Research Respiratory disease SARS-CoV-2 SARS-CoV-2 PCR SARS-CoV-2. severe COVID-19 patients significant decrease significant increase study participant study period subpopulations subset T cell T-cell therapeutic viral respiratory infections were assessed [DOI] 10.1186/s12931-022-02190-8 PMC 바로가기
mRNA-1273 but not BNT162b2 induces antibodies against polyethylene glycol (PEG) contained in mRNA-based vaccine formulationsArticle Published on 2022-10-062022-11-15 Journal: Vaccine [Category] 진단, 치료기술, [키워드] administration Adverse reactions antibodies antibody Antibody Response association BNT162b2 component coronavirus disease correlated COVID-19 detectable drug elicited ELISA enzyme glycerol glycol immune response immunosorbent increase in induce Influenza virus injection Interaction Lipid Lipid nanoparticle low molecular weight Messenger RNA mRNA mRNA vaccine mRNA-1273 mRNA-1273 vaccine mRNA-1273. mRNA-based vaccine participant polyethylene Polyethylene glycol Prevent reactive reactivity SARS-CoV-2 selected sera serum severe allergic reactions vaccination Vaccine vaccine-associated side effect vaccinee [DOI] 10.1016/j.vaccine.2022.08.024 PMC 바로가기
Recent advances in the vaccine development for the prophylaxis of SARS Covid-19Review article Published on 2022-10-012022-10-05 Journal: International immunopharmacology [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 임상, [키워드] acute respiratory syndrome approach co-morbid conditions coronavirus COVID-19 COVID-19 outbreak COVID-19 pandemic COVID-19 vaccine Critical develop Disadvantages Effectiveness Fatality rate global pandemic Government healthcare professionals immune immunization include involved management medication pandemic Pathogenesis platform Prevent Prophylaxis protective immunity public health reactivity recent SARS-CoV-2 Scientific community Spanish flu Spread the vaccine Trial vaccination Vaccinations Vaccine Vaccine development virus [DOI] 10.1016/j.intimp.2022.109175 [Article Type] Review article
Humoral cross-coronavirus responses against the S2 region in children with Kawasaki diseaseArticle Published on 2022-10-012022-11-15 Journal: Virology [Category] COVID19(2023년), SARS, 진단, [키워드] antibodies antibody approach children Control Coronary Coronary aneurysms coronavirus correlated CoV CoVs Cross-immunity cross-reactive cross-reactivity effort explain feature febrile humoral Immunity Infection Inflammatory Kawasaki disease MIS-C multisystem inflammatory syndrome in children OC43 pathology Protein raise reactivity recent Region responses against Safe SARS CoV-2 SARS-CoV-2 SARS-CoV-2 S2 SARS-CoV-2. shown Support syndrome the Spike Vaccine vascular inflammation [DOI] 10.1016/j.virol.2022.08.010 PMC 바로가기
A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjectsArticle Published on 2022-09-292022-11-15 Journal: PLoS ONE [Category] SARS, 변종, 진단, [키워드] antibodies antibody Antigen applied Characteristics Collecting COVID-19 defined determine Dilution dilutions dose doses help humoral Humoral immunity immune response Infection information intensity linear long-lasting MONITOR Pfizer Prevent profile protective immunity quantification quantitative assay RBD reactivity Reinfection Sample SARS-CoV-2 SARS-CoV-2 antigens serological serology test serum sample subject two group vaccination Vaccination strategies Vaccine variant Viral antigen was used were used [DOI] 10.1371/journal.pone.0274553 PMC 바로가기
The impact of platelets on pulmonary microcirculation throughout COVID-19 and its persistent activating factorsArticle Published on 2022-09-282022-11-15 Journal: Frontiers in Immunology [Category] 치료제, [키워드] activate activating addition aggregation antiplatelet Blood coagulation factor complex convalescent COVID-19 COVID-19 patients disease severity disorders endothelial injury Factor Gas exchange hypercoagulability hypercoagulable hypercoagulable states Hypoxemia hypoxia immune cells impaired lung function impairment incidence Inflammation Inflammatory mediators inhibiting Intervention intrinsic involved Lung function manifestation marker microvesicle Microvesicles Mild Mortality Phosphatidylserine Platelet platelet activation Platelets promote PROTECT pulmonary permeability pulmonary vasculitis reactivity reducing resulting risk severe cases stages the disease therapy Thromboembolism thrombosis thrombosis. thrombotic event tissue Treatment vessel walls with COVID-19 [DOI] 10.3389/fimmu.2022.955654 PMC 바로가기